Progress in AML immunotherapy is rapidly advancing, with researchers exploring various antigen targets over the years, including FLT3/CD125, CLL-1, CD33, CD38, CD47, CD70, and others [3, 11, 12]. Here, CD33 is linked to acute myeloid leukemia.